Protypia

Protypia provides a targeted proteomics platform that can precisely quantify drug targeting systems in cells, tissue models, and human tissues. It directly integrates protein-level pharmacology and pathology across multiple therapeutic areas and supports various therapeutic modalities from discovery to clinical development. Founded by Dan Liebler in 2017, Protypia aims to apply emerging mass spectrometry (MS) proteomics technologies to the discovery and development of oncology treatments. Protypia collaborates with an increasing number of leading pharmaceutical and biotechnology companies, focusing on oncology, autoimmune diseases, and gene-editing therapies.